Q fever

被引:1568
作者
Maurin, M [1 ]
Raoult, D [1 ]
机构
[1] Univ Mediterranee, Fac Med, CNRS, UPRES A 6020,Unite Rickettsies, F-13385 Marseille 5, France
关键词
D O I
10.1128/CMR.12.4.518
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Q fever is a zoonosis with a worldwide distribution with the exception of New Zealand. The disease is caused by Coxiella burnetii, a strictly intracellular, gram-negative bacterium. Many species of mammals, birds, and ticks are reservoirs of C. burnetii in nature. C. burnetii infection is most often latent in animals, with persistent shedding of bacteria into the environment. However, in females intermittent high-level shedding occurs at the time of parturition, with millions of bacteria being released per gram of placenta. Humans are usually infected by contaminated aerosols from domestic animals, particularly after contact with parturient females and their birth products. Although often asymptomatic, Q fever may manifest in humans as an acute disease (mainly as a self-limited febrile illness, pneumonia, or hepatitis) or as a chronic disease (mainly endocarditis), especially in patients with previous valvulopathy and to a lesser extent in immunocompromised hosts and in pregnant women. Specific diagnosis of Q fever remains based upon serology. Immunoglobulin M (IgM) and IgG antiphase II antibodies are detected 2 to 3 weeks after infection with C. burnetii, whereas the presence of IgG antiphase I C. burnetii antibodies at titers of greater than or equal to 1:800 by microimmunofluorescence is indicative of chronic Q fever. The tetracyclines are still considered the mainstay of antibiotic therapy of acute Q fever, whereas antibiotic combinations administered over prolonged periods are necessary to prevent relapses in Q fever endocarditis patients. Although the protective role of Q fever vaccination with whole-cell extracts has been established, the population which should be primarily vaccinated remains to be clearly identified. Vaccination should probably be considered in the population at high risk for Q fever endocarditis.
引用
收藏
页码:518 / +
页数:38
相关论文
共 424 条
  • [1] VACCINE PROPHYLAXIS OF Q-FEVER - A FOLLOW-UP-STUDY OF THE EFFICACY OF Q-VAX (CSL) 1985-1990
    ACKLAND, JR
    WORSWICK, DA
    MARMION, BP
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1994, 160 (11) : 704 - 708
  • [2] Q-FEVER IN EUROPE - CURRENT ASPECTS OF ETIOLOGY, EPIDEMIOLOGY, HUMAN INFECTION, DIAGNOSIS AND THERAPY
    AITKEN, ID
    BOGEL, K
    CRACEA, E
    EDLINGER, E
    HOUWERS, D
    KRAUSS, H
    RADY, M
    REHACEK, J
    SCHIEFER, HG
    SCHMEER, N
    TARASEVICH, IV
    TRINGALI, G
    [J]. INFECTION, 1987, 15 (05) : 323 - 327
  • [3] AITKEN ID, 1989, EUR J EPIDEMIOL, V5, P420, DOI 10.1007/BF00140132
  • [4] LYSOSOMAL RESPONSE OF A MURINE MACROPHAGE-LIKE CELL-LINE PERSISTENTLY INFECTED WITH COXIELLA-BURNETII
    AKPORIAYE, ET
    ROWATT, JD
    ARAGON, AA
    BACA, OG
    [J]. INFECTION AND IMMUNITY, 1983, 40 (03) : 1155 - 1162
  • [5] SUPEROXIDE ANION PRODUCTION AND SUPEROXIDE-DISMUTASE AND CATALASE ACTIVITIES IN COXIELLA-BURNETII
    AKPORIAYE, ET
    BACA, OG
    [J]. JOURNAL OF BACTERIOLOGY, 1983, 154 (01) : 520 - 523
  • [6] Alexiou-Daniel S, 1990, HELL IATRIKI, V56, P251
  • [7] AMANO K, 1987, J BIOL CHEM, V262, P4740
  • [8] BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF COXIELLA-BURNETII CELL-WALL AND PEPTIDOGLYCAN-PROTEIN COMPLEX FRACTIONS
    AMANO, KI
    WILLIAMS, JC
    MCCAUL, TF
    PEACOCK, MG
    [J]. JOURNAL OF BACTERIOLOGY, 1984, 160 (03) : 982 - 988
  • [9] CHEMICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LIPOPOLYSACCHARIDES FROM PHASE-I AND PHASE-II COXIELLA-BURNETII
    AMANO, KI
    WILLIAMS, JC
    [J]. JOURNAL OF BACTERIOLOGY, 1984, 160 (03) : 994 - 1002
  • [10] CHRONIC-Q FEVER .2. MORBID ANATOMICAL AND BACTERIOLOGICAL FINDINGS IN A PATIENT WITH ENDOCARDITIS
    ANDREWS, PS
    MARMION, BP
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1959, 2 (NOV14): : 983 - 988